JP2011509079A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509079A5 JP2011509079A5 JP2010540186A JP2010540186A JP2011509079A5 JP 2011509079 A5 JP2011509079 A5 JP 2011509079A5 JP 2010540186 A JP2010540186 A JP 2010540186A JP 2010540186 A JP2010540186 A JP 2010540186A JP 2011509079 A5 JP2011509079 A5 JP 2011509079A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- affinity reagent
- receptor
- ephrin type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003153 chemical reaction reagent Substances 0.000 claims 20
- 101710143005 Ephrin type-A receptor 10 Proteins 0.000 claims 14
- 102100021600 Ephrin type-A receptor 10 Human genes 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 13
- 201000010536 head and neck cancer Diseases 0.000 claims 10
- 208000014829 head and neck neoplasm Diseases 0.000 claims 10
- 206010005003 Bladder cancer Diseases 0.000 claims 9
- 206010006187 Breast cancer Diseases 0.000 claims 9
- 208000026310 Breast neoplasm Diseases 0.000 claims 9
- 206010009944 Colon cancer Diseases 0.000 claims 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 9
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 9
- 206010038389 Renal cancer Diseases 0.000 claims 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 9
- 201000010982 kidney cancer Diseases 0.000 claims 9
- 201000005202 lung cancer Diseases 0.000 claims 9
- 208000020816 lung neoplasm Diseases 0.000 claims 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 9
- 201000002528 pancreatic cancer Diseases 0.000 claims 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 9
- 201000005112 urinary bladder cancer Diseases 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 230000003278 mimic effect Effects 0.000 claims 5
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 4
- 229930193936 anticarin Natural products 0.000 claims 4
- 238000012544 monitoring process Methods 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 230000002946 anti-pancreatic effect Effects 0.000 claims 3
- 239000003560 cancer drug Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 102000012803 ephrin Human genes 0.000 claims 1
- 108060002566 ephrin Proteins 0.000 claims 1
- 239000012642 immune effector Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US877507P | 2007-12-24 | 2007-12-24 | |
| PCT/IB2008/003634 WO2009087462A2 (en) | 2007-12-24 | 2008-12-24 | Ephrin type-a receptor 10 protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011509079A JP2011509079A (ja) | 2011-03-24 |
| JP2011509079A5 true JP2011509079A5 (enExample) | 2012-02-16 |
Family
ID=40802031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010540186A Pending JP2011509079A (ja) | 2007-12-24 | 2008-12-24 | エフリンａ型受容体１０タンパク質 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8540998B2 (enExample) |
| EP (1) | EP2235055A2 (enExample) |
| JP (1) | JP2011509079A (enExample) |
| WO (1) | WO2009087462A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120231004A1 (en) * | 2009-10-13 | 2012-09-13 | Oxford Biotherapeutic Ltd. | Antibodies |
| US8455200B2 (en) | 2009-10-15 | 2013-06-04 | Traxxsson, Llc | Measurement of PKA for cancer detection |
| US20120282177A1 (en) | 2009-11-02 | 2012-11-08 | Christian Rohlff | ROR1 as Therapeutic and Diagnostic Target |
| AU2011299088B2 (en) | 2010-09-09 | 2015-12-24 | Traxxsson, Llc | Combination methods of diagnosing cancer in a patient |
| WO2012124334A1 (ja) * | 2011-03-15 | 2012-09-20 | 独立行政法人医薬基盤研究所 | 抗体、乳がんの治療に用いられる医薬組成物、腫瘍検査方法、及び、腫瘍検査用試薬 |
| EP2726094B1 (en) | 2011-06-28 | 2016-12-14 | Oxford BioTherapeutics Ltd | Therapeutic and diagnostic target |
| GB201213652D0 (en) | 2012-08-01 | 2012-09-12 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| US10081682B2 (en) | 2013-10-11 | 2018-09-25 | Oxford Bio Therapeutics Ltd. | Conjugated antibodies against LY75 for the treatment of cancer |
| GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
| GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| JP2024540616A (ja) * | 2021-11-22 | 2024-10-31 | チャイナ メディカル ユニバーシティ | エフリンａ型受容体１０に特異的な抗体、それを含有する融合タンパク質、それを発現するキメラ抗原受容体ｔ細胞及びその使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030096952A1 (en) | 2000-03-30 | 2003-05-22 | Kumud Majumder | Novel proteins and nucleic acids encoding same |
| AU8394601A (en) * | 2000-07-26 | 2002-02-05 | Merck Patent Gmbh | A novel member of the epha receptor family |
| JP2003052384A (ja) * | 2001-04-06 | 2003-02-25 | Takeda Chem Ind Ltd | 新規レセプタータンパク質及びそのｄｎａ |
| CA2577329A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| CA2585717A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| AU2006287416A1 (en) | 2005-09-07 | 2007-03-15 | Medimmune, Llc | Toxin conjugated Eph receptor antibodies |
| SG177225A1 (en) | 2006-12-01 | 2012-01-30 | Agency Science Tech & Res | Cancer-related protein kinases |
-
2008
- 2008-12-24 JP JP2010540186A patent/JP2011509079A/ja active Pending
- 2008-12-24 EP EP08869234A patent/EP2235055A2/en not_active Withdrawn
- 2008-12-24 US US12/810,095 patent/US8540998B2/en not_active Expired - Fee Related
- 2008-12-24 WO PCT/IB2008/003634 patent/WO2009087462A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011509079A5 (enExample) | ||
| JP2010518847A5 (enExample) | ||
| JP7416625B2 (ja) | 早期バイオマーカーを使用する、頭部への損傷を負ったヒト対象又は負った可能性があるヒト対象に対して、イメージングを実施するかどうかの決定の一助となるための方法 | |
| Huang et al. | Nanobodies®: proficient tools in diagnostics | |
| JP7269182B2 (ja) | 心臓トロポニンｉ及び早期バイオマーカーを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法 | |
| JP6715770B2 (ja) | モノクローナル抗ｔｋ１抗体 | |
| JP6180931B2 (ja) | 癌の診断および／または予後のための新規な抗体 | |
| JP2015172045A5 (enExample) | ||
| JP2018042573A5 (enExample) | ||
| JP2012523848A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| JP6239503B2 (ja) | 新規な抗ｃｘｃｒ４抗体並びに癌の検出および診断のためのその使用 | |
| JP2020522261A5 (enExample) | ||
| JP2015516985A5 (enExample) | ||
| JP2017518366A5 (enExample) | ||
| CA2947932A1 (en) | Pd-l1 antibodies and uses thereof | |
| JP2013520174A5 (enExample) | ||
| JP2020534830A5 (enExample) | ||
| JP2016500659A5 (enExample) | ||
| Kadonosono et al. | Design strategy to create antibody mimetics harbouring immobilised complementarity determining region peptides for practical use | |
| EP3094976A1 (en) | Cell surface prostate cancer antigen for diagnosis | |
| JP2010535506A5 (enExample) | ||
| Dhaouadi et al. | Novel human tenascin-C function-blocking camel single domain nanobodies | |
| AU2016333540A1 (en) | GDF-15 as a diagnostic marker for melanoma | |
| JP2016511767A5 (enExample) |